查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961148

中軸型脊椎關節炎市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、藥物類別、地區和競爭格局分類，2021-2031年

Axial Spondyloarthritis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Class, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球中軸型脊椎關節炎 (axSpA) 市場預計將從 2025 年的 60.8 億美元成長到 2031 年的 83.1 億美元，複合年成長率為 5.32%。

此領域涵蓋頻譜慢性發炎性風濕病，包括僵直性脊椎炎及其非放射性變異型，主要涉及脊椎和骶髂關節。市場成長的主要驅動力是自體免疫疾病盛行率的上升以及先進生物療法（尤其是白細胞介素抑制劑）在臨床上的應用日益廣泛。此外，價格合理的生物相似藥獲得監管部門核准以及篩檢措施的改進，使得患者更容易獲得必要的治療，從根本上推動了該行業的成長趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 60.8億美元
市場規模：2031年 83.1億美元
複合年成長率：2026-2031年 5.32%
成長最快的細分市場 非類固醇消炎劑（NSAIDs）
最大的市場 北美洲

儘管取得了這些進展，但臨床診斷的顯著延遲仍然是市場發展的主要障礙，阻礙了及時治療性介入。低診斷效率限制了能夠接受治療的患者數量，並使長期疾病管理工作更加複雜。根據國際中軸型脊椎關節炎聯盟（ASF）2024年的報告，全球患者從症狀出現到正式確診的平均延遲時間為7.4年。如此長的潛伏期是實現患者最佳治療效果的重大障礙，也阻礙了市場充分發揮其滲透潛力。

市場促進因素

新型IL-17抑制劑和JAK抑制劑的商業化正在從根本上改變中軸型脊椎關節炎的治療格局，為對傳統TNF抑制劑抗藥性的患者提供標靶治療。這些先進的藥物療法能夠有效治療放射學觀察陽性和非放射學陽性的脊椎關節炎，從而有效擴大了目標患者群體，並迅速擴大了市場佔有率。此外，它們已被證實能夠減輕發炎並預防脊椎結構損傷，這推動了其應用。例如，諾華公司在2024年10月發布的2024年第三季財報中宣布，其IL-17抑制劑Cosentyx的季度全球銷售額達到17億美元。此外，口服JAK抑制劑的使用也日益增多，與注射劑相比，口服JAK抑制劑具有更方便的給藥方式。艾伯維公司2024年第三季財報顯示，其Rinvoc的全球淨銷售額達到16.1億美元，進一步顯示了市場對這些創新作用機制的高度認可。

市場擴張的另一個驅動力是強大的下一代生物製劑臨床研發管線，其中包括旨在實現更高緩解率的雙重細胞激素抑制劑和奈米抗體。這些新型候選藥物的不斷湧現，創造了競爭激烈的市場環境，並透過改善治療可及性和差異化的作用機制促進了成長。特別是，雙重IL-17A/IL-17F抑制劑的出現，有望在臨床試驗中展現優於傳統標準療法的皮膚和關節症狀改善效果。為了佐證這項快速普及，UCB於2024年7月發布的「2024會計年度上半年報告」顯示，新上市的生物製藥Bimzelx在上半年的淨銷售額達到2.15億歐元，這充分展現了研發管線的活力，並將確保市場的長期永續發展。

市場挑戰

臨床診斷的嚴重延誤是限制全球中軸型脊椎關節炎 (axSpA) 市場商業性擴張的主要瓶頸。這種低下的診斷效率實際上將很大一部分目標患者群體限制在基層醫療和非風濕病診療機構，而這些機構通常不提供或不承保先進的生物製藥療法。因此，由於患者長期未接受治療或僅接受特異性干預，製藥公司面臨目標市場規模顯著縮小的挑戰。由於這些患者進入風濕病專科診療路徑的時間遠晚於最佳時機，高價值療法的獲利能力受到直接限制，有效的早期療育策略也常常被錯失。

這種分散的轉診途徑嚴重阻礙了市場滲透，造成了疾病高發生率與實際治療啟動之間的巨大差距。根據美國僵直性脊椎炎協會預測，到2024年，四分之一的患者需要諮詢五位或更多醫療專業人員才能獲得診斷。如此複雜的轉診途徑降低了篩檢效率，並延誤了生物製劑治療的啟動。除非彌合這一轉診差距，否則市場將無法充分利用疾病的真實發病率，巨大的商業性價值也將無法充分挖掘。

市場趨勢

將人工智慧增強型磁振造影技術應用於疾病早期檢測，正成為全球中軸型脊椎關節炎（axSpA）市場的關鍵趨勢。演算法被應用於掃描分析，能夠自動識別常規檢查中常被忽略的發炎標記物，從而縮短診斷時間。 UCB製藥公司於2024年10月發表的一項題為「深度學習演算法效能分析」的研究報告指出，一種用於檢測骶髂關節發炎的新型人工智慧模型與放射科專家的診斷結果完全一致，達到74%。此類創新對於提供標準化工具以區分axSpA和機械性腰痛，以及縮短治療性介入時間至關重要。

同時，生物相似藥TNF抑制劑的市場滲透率不斷提高，正在重塑整個產業的競爭格局。醫療保健系統正在推動向這些更具成本效益的傳統生物製藥替代方案轉變，從而有效提高了治療的可及性。Adalimumab市場主導地位的削弱清晰地體現了這一變化，處方集的變化加速了銷售量從原廠藥物轉移到生物相似藥的情況。正如三星生物製劑公司於2024年10月發布的《2024年第四季美國生物相似藥市場報告》中所述，Adalimumab生物相似藥在美國的市佔率從2024年初的2%成長到同年8月的22%。這一趨勢迫使原廠藥生產商在價格上競爭，同時也為新的治療機制創造了資金空間。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：中軸型脊椎關節炎（axSpA）全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（僵直性脊椎炎（AS）、非放射性中軸型脊椎關節炎（nr-axSpA））
    • 藥物分類（非類固醇消炎劑（NSAIDs）、糖皮質素、抗風濕藥、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美中軸型脊椎關節炎（axSpA）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲中軸型脊椎關節炎（axSpA）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區中軸型脊椎關節炎（axSpA）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲軸性脊椎關節炎（axSpA）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲軸性脊椎關節炎（axSpA）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球中軸型脊椎關節炎（axSpA）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • UCB SA
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • GlaxoSmithKline plc
  • NorthStar Rx LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23171

The Global Axial Spondyloarthritis (axSpA) Market is projected to expand from USD 6.08 billion in 2025 to USD 8.31 billion by 2031, reflecting a compound annual growth rate of 5.32%. This sector encompasses a spectrum of chronic inflammatory rheumatic conditions, including ankylosing spondylitis and non-radiographic variants, which primarily impact the spine and sacroiliac joints. The growth of this market is largely fueled by the rising prevalence of autoimmune disorders and the increasing clinical adoption of advanced biologic therapies, particularly interleukin inhibitors. Additionally, the regulatory approval of affordable biosimilars and the implementation of enhanced screening initiatives are improving patient access to essential treatments, thereby fundamentally supporting the industry's upward trajectory.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.08 Billion
Market Size 2031USD 8.31 Billion
CAGR 2026-20315.32%
Fastest Growing SegmentNon-steroidal anti-inflammatory drugs (NSAID)
Largest MarketNorth America

Despite these advancements, the market faces a significant hurdle due to substantial delays in clinical identification, which hinder timely therapeutic intervention. This diagnostic inefficiency limits the accessible patient population and complicates long-term disease management efforts. In 2024, the Axial Spondyloarthritis International Federation reported that patients worldwide experienced an average delay of 7.4 years between the onset of symptoms and receiving a formal diagnosis. Such prolonged latency periods remain a critical barrier to achieving optimal patient outcomes and restrict the market from realizing its full penetration potential.

Market Driver

The commercialization of novel IL-17 and JAK inhibitor therapies is fundamentally reshaping the treatment landscape for axial spondyloarthritis by providing targeted efficacy for patients who are resistant to traditional TNF inhibitors. These advanced pharmacotherapies are rapidly gaining market share due to their ability to treat both radiographic and non-radiographic variants of the disease, effectively widening the eligible patient pool. Their adoption is further driven by a proven capability to reduce inflammation and prevent structural spinal damage; for instance, Novartis reported in its "Q3 2024 Financial Results" in October 2024 that global sales for the IL-17 inhibitor Cosentyx reached USD 1.7 billion for the quarter. Furthermore, the sector is seeing a shift toward oral JAK inhibitors, which offer administration convenience over injectables, with AbbVie's "Third-Quarter 2024 Financial Results" noting that global net revenues for Rinvoq hit USD 1.61 billion, underscoring the high value placed on these innovative mechanisms.

Market expansion is also being propelled by a robust clinical pipeline of next-generation biologics, including dual-cytokine inhibitors and nanobodies aimed at achieving deeper remission rates. This continuous influx of new candidates creates a competitive environment that improves treatment accessibility and stimulates growth through differentiated mechanisms of action. Notably, the emergence of dual IL-17A and IL-17F inhibitors has shown promise in clinical trials for delivering superior skin and joint clearance compared to earlier standards. Highlighting this rapid uptake, UCB's "Half-Year Report 2024" in July 2024 revealed that net sales for the recently launched biologic Bimzelx reached EUR 215 million in the first six months, demonstrating the vitality of a pipeline that ensures long-term market resilience.

Market Challenge

The significant latency in clinical diagnosis acts as a primary bottleneck that restricts the commercial expansion of the global axSpA market. This diagnostic inefficiency effectively isolates a large portion of the eligible patient population within primary care or non-rheumatological settings, where advanced biologic therapies are typically neither prescribed nor reimbursed. Consequently, pharmaceutical manufacturers encounter a considerably reduced addressable market, as patients remain untreated or are managed with non-specific interventions for extended periods. The revenue potential of high-value therapeutics is directly curtailed because these individuals enter the specialized rheumatology channel much later than optimal, often missing the window for effective early intervention strategies.

This fragmented referral pathway significantly hampers market penetration rates by creating a disconnect between the high prevalence of the disease and actual therapeutic adoption. According to the Spondylitis Association of America, in 2024, one in four patients consulted five or more healthcare professionals in search of a diagnosis. Such convoluted clinical journeys dilute the efficiency of screening initiatives and delay the initiation of biologic treatments. Until this referral gap is successfully bridged, the market will struggle to capitalize on the true prevalence of the disease, leaving a significant amount of commercial value unrealized.

Market Trends

The integration of AI-enhanced MRI for early disease detection is developing into a critical trend within the Global Axial Spondyloarthritis (axSpA) Market. Algorithms are now being utilized to analyze scans and automate the identification of inflammatory markers that are frequently missed during standard reviews, thereby countering diagnostic latency. A study by UCB Pharma in October 2024, titled "Performance analysis of a deep-learning algorithm," reported that a novel AI model for detecting sacroiliac joint inflammation achieved a 74% absolute agreement rate with expert readers. These innovations are pivotal for providing standardized tools to distinguish axSpA from mechanical back pain and for accelerating the timeline for therapeutic intervention.

Concurrently, the rising market penetration of biosimilar TNF inhibitors is restructuring competitive dynamics across the sector. Healthcare systems are increasingly incentivizing these cost-efficient alternatives to legacy biologics, which is effectively expanding treatment accessibility. This shift is highlighted by the erosion of market exclusivity for adalimumab, where formulary changes are driving volume transitions away from reference products. As noted by Samsung Bioepis in their "Fourth Quarter 2024 US Biosimilar Market Report" from October 2024, the market share for adalimumab biosimilars in the United States grew from 2% in early 2024 to 22% by August 2024. This trend forces originator manufacturers to compete on price while simultaneously opening fiscal space for newer therapeutic mechanisms.

Key Market Players

  • UCB S.A.
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • GlaxoSmithKline plc
  • NorthStar Rx LLC

Report Scope

In this report, the Global Axial Spondyloarthritis (axSpA) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Axial Spondyloarthritis (axSpA) Market, By Type

  • Ankylosing spondylitis (AS)
  • Non- radiographic axial spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (axSpA) Market, By Drug Class

  • Non-steroidal anti-inflammatory drugs (NSAID)
  • Glucocorticoids
  • Anti-rheumatic drugs
  • Others

Axial Spondyloarthritis (axSpA) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Axial Spondyloarthritis (axSpA) Market.

Available Customizations:

Global Axial Spondyloarthritis (axSpA) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Axial Spondyloarthritis (axSpA) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Ankylosing spondylitis (AS), Non- radiographic axial spondyloarthritis (nr-axSpA))
    • 5.2.2. By Drug Class (Non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, Anti-rheumatic drugs, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Axial Spondyloarthritis (axSpA) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug Class
    • 6.3.2. Canada Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug Class
    • 6.3.3. Mexico Axial Spondyloarthritis (axSpA) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug Class

7. Europe Axial Spondyloarthritis (axSpA) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug Class
    • 7.3.2. France Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug Class
    • 7.3.3. United Kingdom Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug Class
    • 7.3.4. Italy Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug Class
    • 7.3.5. Spain Axial Spondyloarthritis (axSpA) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug Class

8. Asia Pacific Axial Spondyloarthritis (axSpA) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug Class
    • 8.3.2. India Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug Class
    • 8.3.3. Japan Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug Class
    • 8.3.4. South Korea Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug Class
    • 8.3.5. Australia Axial Spondyloarthritis (axSpA) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug Class

9. Middle East & Africa Axial Spondyloarthritis (axSpA) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug Class
    • 9.3.2. UAE Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug Class
    • 9.3.3. South Africa Axial Spondyloarthritis (axSpA) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug Class

10. South America Axial Spondyloarthritis (axSpA) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug Class
    • 10.3.2. Colombia Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug Class
    • 10.3.3. Argentina Axial Spondyloarthritis (axSpA) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Axial Spondyloarthritis (axSpA) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. UCB S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Abbott Laboratories Inc.
  • 15.4. Johnson & Johnson
  • 15.5. Merck & Co., Inc.
  • 15.6. AbbVie Inc.
  • 15.7. Novartis AG
  • 15.8. Eli Lilly and Company
  • 15.9. Amgen Inc.
  • 15.10. GlaxoSmithKline plc
  • 15.11. NorthStar Rx LLC

16. Strategic Recommendations

17. About Us & Disclaimer